Delgocitinib

Delgocitinib poster presentations will include new data from the Phase 3 DELTA TEEN Trial as well as findings from a wide range of health economics and outcomes research and real-world evidence 1-9 Multiple poster presentations will feature new data on real-world clinical characteristics and treatment patterns among patients with GPP 10-14 MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma, Inc., a global leader in medical dermatology, today announced its scientific program for the 2026 Fall Clinical Dermatology Conference, taking place October 8-11 in Las Vegas, Nevada. Among the 21 posters are presentations of new data on delgocitinib in chronic hand eczema (CHE), spesolimab in generalized pustular psoriasis (GPP), and tralokinumab in atopic dermatitis (AD). Other presentations include findings to characterize disease prevalence and burden among people with CHE, GPP and pyoderma gangrenosum (PG). 1-21 New safety data from the Phase 3 DELTA TEEN trial will be shared that provide a greater understanding of the potential use of delgocitinib cream for adolescents with moderate to severe CHE. 1,2 The use of delgocitinib in adolescents has been submitted for U.S. regulatory approval. The safety and efficacy of delgocitinib in this patient population has not been approved by the FDA. Additional posters will highlight health economics and outcomes research data on the impact of CHE on work productivity, quality of life and daily functioning of adults living with the condition. 8,9 Several presentations will focus on GPP, a chronic, potentially life-threatening rare skin disease. 10-14, 22 Data to be presented include long-term data and real-world use of spesolimab, as well as new research characterizing the U.S. prevalence and clinical characteristics of people living with GPP. 10-14 Data to be presented on tralokinumab include real-world effectiveness and safety outcomes from the non-interventional TRACE study in adults with AD. 15 “We look forward to sharing our latest safety data from the Phase 3 DELTA TEEN trial, along with new real-world data and treatment patterns that characterize the impact of living with chronic hand eczema and other challenging dermatologic conditions,” said Shannon Schneider, Vice President of North America Medical Affairs for LEO Pharma. “The research presented this year reflects LEO Pharma’s continued commitment to advancing medical dermatology and addressing gaps in the care of patients living with chronic hand eczema, generalized pustular psoriasis, atopic dermatitis and pyoderma gangrenosum.” The company’s full roster of presentations at the 2026 Fall Clinical Dermatology Conference appears below. All 21 posters will be on display in the Poster Gallery in Cristal 1, 3, 5 and 7 at Wynn Las Vegas starting at 1:00 p.m. PDT on October 8, 2026. 1-21 Delgocitinib and Chronic Hand Eczema Characteristics of adult patients treated with delgocitinib for chronic hand eczema in the United States: A retrospective claims-based analysis Author: April W. Armstrong Greater burden of chronic hand eczema among patients with higher Monk skin tones: Findings from the cross-sectional study, CHECK-US Author: Raj Chovatiya Baseline burden and treatment history of adolescents with moderate to severe Chronic Hand Eczema (CHE) enrolled in the randomized phase 3 DELTA TEEN trial Author: Sonja Molin The DELTA TEEN phase 3 trial: Systemic exposure and safety pro delgocitinib cream in adolescents with moderate to severe chronic hand eczema Author: Sonja Molin Study design of a prospective observational Chronic Hand Eczema (CHE) registry to describe real-world outcomes of CHE treatments in the US and Canada Author: Jonathan I. Silverberg High topical corticosteroid utilization among employed patients with chronic hand eczema: A survey of patients in a large integrated healthcare system in the United States Author: Stefan C. Weiss Impaired work productivity in adults with chronic hand eczema: A survey of patients in a large integrated healthcare system in the United States Author: Stefan C. Weiss Quality of life and daily functioning impairment among working adults with chronic hand eczema in a large integrated healthcare system in the United States Author: Stefan C. Weiss Encore Presentations Treatment patterns in chronic hand eczema in the US - Results from the RWEAL-US medical chart review Author: Raj Chovatiya Spesolimab and Generalized Pustular Psoriasis GPP OBSERVE: Real-world clinical characteristics and treatment patterns among patients with generalized pustular psoriasis in the United States Author: Mark G. Lebwohl Real-world use of subcutaneous spesolimab for ongoing disease control in generalized pustular psoriasis: A report of two patient cases Author: Sarah L. Lonowski Prevalence and baseline characteristics of patients with Generalized Pustular Psoriasis (GPP) in the United States from 2016 to 2025 Author: Mona Nili Encore Presentations Intravenous spesolimab for (re)treatment of generalized pustular psoriasis flares in patients receiving subcutaneous spesolimab: Results from the 5-year, open-label, EFFISAYIL ON extension study Author: Kenneth Gordon Long-term (≥3 year) efficacy and safety of subcutaneous spesolimab for treatment of generalized pustular psoriasis: Results from the EFFISAYIL program Author: Johann Gudjonsson Tralokinumab and Atopic Dermatitis Real-world effectiveness in combination with absence of treatment-related adverse events at assessed visits through 12 months of tralokinumab treatment in the non-interventional TRACE study Author: April W. Armstrong Tralokinumab shifts skin lipid and natural moisturizing factor biomarkers toward a healthier pro children with moderate-to-severe atopic dermatitis in the phase 2 TRAPEDS 1 trial Author: Michael J. Cork Encore Presentations Real-world characterization of early and delayed responses to tralokinumab among patients with atopic dermatitis: Results from the prospective, international, non-interventional 12-month TRACE study Author: April W. Armstrong Real-world use of tralokinumab in patients with atopic dermatitis involving high-burden areas: Effectiveness and impact on quality of life in the prospective, non-interventional 12-month TRACE study Author: April W. Armstrong Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema Author: Benjamin D. Ehst Tralokinumab monotherapy rapidly improves sleep, daily functions, and health-related quality of life in patients with atopic dermatitis and moderate-to-severe hand involvement Author: Sebastian Volc Pyoderma Gangrenosum Pyoderma gangrenosum in the United States: Incidence and prevalence estimates from a large administrative claims database Author: Arash Mostaghimi About Chronic Hand Eczema Chronic Hand Eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. 23 CHE is one of the most common skin diseases of the hands, affecting nearly 1 in 10 people worldwide. 23, 24 CHE is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists. 23 CHE has been shown to cause psychological and functional burdens that impact patient quality of life, 25,26 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the disease. 27 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE. 28 About Generalized Pustular Psoriasis Generalized pustular psoriasis (GPP) is a chronic, heterogeneous, neutrophilic autoinflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment. 29,30 GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems. 22,31 GPP symptoms appear unpredictably and present on a continuum, which greatly impacts a patient’s quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities and finances. 31,32 About Atopic Dermatitis Atopic Dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions. 33 AD is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation. 34 Type 2 cytokines, including IL-13, play an important role in the key aspects of AD pathophysiology. 33,34 Excessive IL-22 production is also known to contribute to the pathogenesis of AD. 35 About Pyoderma Gangrenosum Pyoderma Gangrenosum (PG) is a rare, severe, systemic neutrophilic inflammatory disease that rapidly progresses to painful ulcers that may occur spontaneously or be triggered by trauma or certain medications. 36,37 PG has an unpredictable clinical course and patients with PG experience substantial disease burden due to severe pain and impaired quality of life. 36,38 Variability in clinical presentation, lack of clear diagnostic criteria, and frequent misidentification contribute to a limited understanding of PG incidence and prevalence in the U.S. 39,40 About ANZUPGO ® (delgocitinib) Cream ANZUPGO cream is a topical and non-steroidal pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE. 24,41 ANZUPGO (delgocitinib) cream is FDA approved in the U.S. for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA. 41 ANZUPGO is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. 42 ANZUPGO cream is also under investigation in other markets. In 2014, LEO Pharma obtained the exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where Shionogi & Co., Ltd. owns the rights. ANZUPGO HCP INDICATION and IMPORTANT SAFETY INFORMATION: INDICATION ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Limitations of Use : Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Serious Infections: ANZUPGO may increase the risk of infections. Eczema herpeticum was observed in a subject treated with ANZUPGO. Serious and sometimes fatal infections have been reported in patients receiving oral or topical JAK inhibitors. Avoid use in patients with an active or serious infection. Consider risks and benefits before initiating ANZUPGO in patients with chronic or recurrent infection; tuberculosis exposure; history of serious or opportunistic infection; or underlying conditions that may predispose to infection. Monitor for signs and symptoms of infection during and after treatment. Interrupt ANZUPGO if a serious infection develops; do not resume until the infection resolves or is adequately treated. Viral reactivation, including herpes virus reactivation (e.g., herpes zoster), was reported in clinical trials with ANZUPGO. If herpes zoster develops, consider interrupting ANZUPGO until the episode resolves. The impact of ANZUPGO on chronic viral hepatitis reactivation is unknown; consider viral hepatitis screening and monitoring per clinical guidelines before and during therapy. If signs of reactivation occur, consult a hepatitis specialist. ANZUPGO is not recommended in patients with active hepatitis B or C. Non-melanoma Skin Cancers: Non-melanoma skin cancers, including basal cell carcinoma, have been reported. Periodic skin examinations of application sites are recommended for all patients, particularly for patients with risk factors for skin cancer. Advise patients to avoid sunlamps and minimize sunlight exposure. Immunizations: Prior to ANZUPGO, complete all age-appropriate vaccinations per current immunization guidelines, including herpes zoster vaccinations. Avoid live vaccines immediately prior to, during, and immediately after ANZUPGO treatment. Potential Risks Related to JAK Inhibition: It is not known whether ANZUPGO may be associated with the observed or potential adverse reactions of JAK inhibition. In a safety trial of an oral JAK inhibitor with methotrexate in RA, patients ≥50 years with ≥1 cardiovascular risk factor had higher rates of all-cause mortality (including sudden cardiovascular death), MACE, overall thrombosis, DVT, PE, and malignancies (excluding non-melanoma skin cancer) versus TNF blockers. ANZUPGO is not indicated for use in rheumatoid arthritis (RA). Oral and topical JAK inhibitors have been associated with increased lipids (total cholesterol, LDL cholesterol, triglycerides). Oral JAK inhibitors have caused hypoglycemia in patients with diabetes. ADVERSE REACTIONS Adverse reactions reported in ≤1% of subjects were application site pain, paresthesia, pruritus, erythema, and bacterial skin infections, including finger cellulitis, paronychia, other skin infections, leukopenia, and neutropenia. USE IN SPECIFIC POPULATIONS Lactation: To minimize potential infant exposure, advise breastfeeding women to avoid direct contact with the nipple and surrounding area immediately after applying ANZUPGO to the hands and/or wrists. Please see full Prescribing Information and Medication Guide . About SPEVIGO ® (spesolimab-sbzo) SPEVIGO ® (spesolimab-sbzo) is a humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. 43 It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP. 44-46 SPEVIGO CONSUMER INDICATION and IMPORTANT SAFETY INFORMATION: INDICATION SPEVIGO is a prescription medicine used to treat generalized pustular psoriasis (GPP) in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg). It is not known if SPEVIGO is safe and effective in children under 12 years of age or who weigh less than 88 pounds (40 kg). IMPORTANT SAFETY INFORMATION Do not receive SPEVIGO if you or your child have had a severe or life-threatening allergic reaction to spesolimab-sbzo or any of the ingredients in SPEVIGO. SPEVIGO may cause serious side effects, including: Infections: SPEVIGO may lower the ability of your or your child’s immune system to fight infections and may increase your or your child’s risk of infections. Your healthcare provider should check you or your child for infections and tuberculosis (TB) before starting treatment with SPEVIGO and may treat you or your child for TB before you begin treatment with SPEVIGO if you have a history of TB or have active TB. Your healthcare provider should watch you or your child closely for signs and symptoms of TB during or after treatment with SPEVIGO. Tell your healthcare provider right away if you or your child have an infection or have symptoms of an infection during or after treatment with SPEVIGO, including, fevers, chills, or sweats, muscle aches, cough, shortness of breath, blood in your phlegm (mucus), burning when you urinate, urinating more often than normal Allergic reactions and infusion-related reactions: Serious allergic reactions may happen during or after your or your child’s SPEVIGO injection. If you or your child have a serious allergic reaction, your healthcare provider will stop treatment with SPEVIGO. If you or your child are given SPEVIGO in a vein (intravenously) and have an infusion-related reaction, your healthcare provider will stop your or your child’s SPEVIGO infusion and treat your or your child’s symptoms and may restart SPEVIGO at a slower infusion rate. Tell your healthcare provider or get emergency medical help right away if you or your child get any of the following symptoms during or after your or your child’s SPEVIGO injection: feeling faint, dizzy, or lightheaded, swelling of your face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness, fever, mouth sores, chest tightness, hives or skin rash that is different than the rash from generalized pustular psoriasis (GPP), itching, swollen lymph nodes Before you or your child receive SPEVIGO, tell your healthcare provider about all of your medical conditions, including if you or your child: have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). You or your child should not receive live vaccines during and for at least 16 weeks after treatment with SPEVIGO. You or your child should be brought up to date with all vaccines before starting SPEVIGO. are pregnant or plan to become pregnant. It is not known if SPEVIGO can harm your or your child’s unborn baby. are breastfeeding or plan to breastfeed. It is not known if SPEVIGO passes into your breast milk. Talk to your healthcare provider about the best way to feed your or your child’s baby during treatment with SPEVIGO. The most common side effects of SPEVIGO given in a vein (intravenously) for GPP flare treatment include feeling tired or weak, headache, nausea, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, urinary tract infection The most common side effects of SPEVIGO when given under the skin (subcutaneously) for treatment of GPP when not experiencing a flare include redness, pain, swelling, hardening, hives, or warmth at the injection site, joint pain, urinary tract infection, itching These are not all of the possible side effects of SPEVIGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please see full Prescribing Information , including Medication Guide and Instructions for Use . About ADBRY ® (tralokinumab-ldrm)/ADTRALZA ® (tralokinumab) ADBRY ® (tralokinumab-ldrm), which is marketed outside of the U.S. under the tradename ADTRALZA ® (tralokinumab), is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms. 47,48 Tralokinumab specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2). 49 Tralokinumab is approved for the treatment of moderate-to-severe AD in adult and adolescent patients 12 years and older in the European Union, Canada, Great Britain, the United Arab Emirates, South Korea, the U.S., and Saudi Arabia. Tralokinumab is approved for use in adults with moderate- to-severe AD in Switzerland and Japan. ADBRY HCP INDICATION and IMPORTANT SAFETY INFORMATION: INDICATION ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ADBRY is contraindicated in patients with known hypersensitivity to its ingredients. WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis and angioedema, have occurred. If a serious hypersensitivity reaction occurs, discontinue immediately and initiate appropriate therapy. Conjunctivitis and keratitis have occurred, and conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms. Treat patients with preexisting parasitic infections before initiating ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue ADBRY until the infection resolves. ADBRY may alter a patient’s immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccines according to guidelines. Avoid use of live vaccines during treatment. ADVERSE REACTIONS Common adverse reactions include upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia. USE IN SPECIFIC POPULATIONS There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADBRY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves. There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. There are no data on the presence of ADBRY in human milk, the effects on the breastfed infant, or the effects on milk production. Please see full Prescribing Information , including Patient Information and Instructions for Use . About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,400 people worldwide. Together, we reach far beyond the skin. For more information, visit . References: Molin S, et al. Baseline burden and treatment history of adolescents with moderate to severe Chronic Hand Eczema (CHE) enrolled in the randomized phase 3 DELTA TEEN trial. Presented at the Fall Clinical Dermatology Conference 2026. Las Vegas, Nevada. 8-11 Oct. Poster Presentation. Molin S, et al. The DELTA TEEN phase 3 trial: Systemic exposure and safety pro delgocitinib cream in adolescents with moderate to severe chronic hand eczema. Presented at the Fall Clinical Dermatology Conference 2026. Las Vegas, Nevada. 8-11 Oct. Poster Presentation. Armstrong A, et al. Characteristics of adult patients treated with delgocitinib for chronic hand eczema in the United States: A retrospective claims-based analysis. Presented at the Fall Clinical Dermatology Conference 2026. Contacts Samantha Cranko LEO Pharma External Communications, North America Email: media@leo-pharma.com Read full story here

Delgocitinib和卢可替尼都是非激素外用JAK抑制剂，也都可以阻断皮肤炎症信号。于是，不少患者会问：两种药是不是差不多？哪个治疗特应性皮炎效果更好？0.5%和1.5%是否代表卢可替尼更强？ 先说结论：两者属于同一大类，但不是同一种药。它们的JAK选择性、浓度、剂型、获批适应证、年龄范围、涂抹面积和安全警示均有差异，不能根据浓度百分比判断强弱，也不能自行互换。 本文主要比较日本Corectim说明书与美国Opzelura说明书。不同国家和地区的批准状态可能不同。两种外用JAK抑制剂有什么核心区别？ 对比项目 Delgocitinib 卢可替尼 常见商品名 Corectim Opzelura 代表性规格 0.5%、0.25%软膏 1.5%乳膏 主要JAK靶点 JAK1、JAK2、JAK3、TYK2 主要抑制JAK1、JAK2 药物特点 广谱或pan-JAK抑制剂 JAK1/2抑制剂 日本获批适应证 特应性皮炎 日本批准状态需以当地资料为准 美国主要适应证 尚非美国特应性皮炎常规产品 特应性皮炎、非节段型白癜风 用药频率 通常每日2次 通常每日2次 是否激素 否 否 两者最大的区别不是“一个0.5%、一个1.5%”，而是药物分子、制剂配方和临床研究体系不同。 1.5%只说明每克卢可替尼乳膏中所含药物的比例，不能证明它的抗炎强度是0.5% Delgocitinib的三倍。不同药物之间不能直接比较百分比。作用机制有什么不同？ 特应性皮炎发生时，多种细胞因子会通过JAK—STAT通路传递炎症及瘙痒信号。 Delgocitinib能够抑制JAK1、JAK2、JAK3和TYK2，因此常被称为广谱JAK抑制剂。日本药理资料显示，它可以减少免疫细胞和炎症细胞活化，并抑制IL-31诱发的搔抓行为。 卢可替尼主要抑制JAK1和JAK2。除了干预特应性皮炎相关的炎症通路，它还能阻断与白癜风免疫攻击有关的信号，因此美国FDA同时批准其用于部分非节段型白癜风患者的复色治疗。 靶点更多不等于临床效果一定更强。药物实际疗效还取决于皮肤渗透、局部浓度、用量、疾病类型及患者个体差异。获批适应证有什么区别？ 日本Corectim软膏的批准适应证是特应性皮炎。日本说明书并未将白癜风列为其常规适应证，也不能因为同属JAK抑制剂，就自行用来治疗白斑。 美国Opzelura乳膏目前主要用于两类疾病： 第一类是免疫功能未受损患者的轻至中度特应性皮炎，用于其他处方外用治疗控制不足，或者不适合使用这些治疗的患者。美国适用年龄已经扩展至2岁及以上。 第二类是12岁及以上成人和儿童的非节段型白癜风。 因此，如果治疗目标是白癜风，卢可替尼拥有相应的监管批准与临床研究基础；如果讨论日本成人或儿童特应性皮炎，Corectim则拥有日本本土的0.5%和0.25%用药体系。成人和儿童的用法一样吗？ 日本Delgocitinib的用法比较强调年龄与浓度： 成人通常使用0.5%软膏，每日两次，每次最多5克；儿童通常从0.25%开始，每日两次，根据病情可由医生调整至0.5%。儿童使用0.5%后症状改善，应考虑降回0.25%。 单次涂抹范围原则上不超过约30%的体表面积。低出生体重儿、新生儿及6个月以下婴儿缺少充分临床试验数据。 美国卢可替尼1.5%乳膏治疗特应性皮炎时，通常也是每日两次，但涂抹范围限制更严格，一般不超过20%的体表面积，并有每周或每两周最大用量限制。治疗白癜风时，涂抹面积通常不超过10%体表面积。 这些差异说明，两种药不能按照同一支数、同一面积或同一疗程直接替换。哪种治疗特应性皮炎效果更好？ 目前缺少能够直接回答这一问题的高质量头对头研究。 Delgocitinib成人Ⅲ期研究以治疗4周时的mEASI变化作为主要终点，0.5%组平均下降44.3%，安慰剂组上升1.7%。 卢可替尼的关键研究通常在8周时使用研究者总体评估、瘙痒改善等指标评价疗效。 由于两种研究的入组人群、治疗周期、疾病严重程度及主要终点不同，不能把研究中的两个百分比放在一起，宣布某一种药“疗效更强”。 临床选择更应关注：患者年龄、疾病类型、皮损面积、既往治疗、当地批准适应证以及能否规范随访。副作用有哪些不同？ Delgocitinib较明确的局部不良反应包括： 涂抹部位毛囊炎； 痤疮样皮疹； 刺激感、红斑和瘙痒； 接触性皮炎； 疱疹性湿疹、单纯疱疹、带状疱疹或脓痂疹。 卢可替尼乳膏也可能出现涂抹部位痤疮、瘙痒、红斑、毛囊炎，以及鼻咽炎、头痛等不良反应。 美国卢可替尼说明书还带有JAK抑制剂类别相关的严重感染、恶性肿瘤、重大心血管事件和血栓等警示。这些严重风险主要来自系统性JAK抑制剂的观察，但监管说明书仍要求外用卢可替尼患者关注相关风险，并避免与其他JAK抑制剂、生物制剂或强效免疫抑制剂随意联用。 不能据此简单得出“Delgocitinib一定比卢可替尼安全”，因为两个国家的监管格式和风险警示体系不同，临床数据也不能直接横向比较。两种药都能长期使用吗？ 两者都不适合被当成普通保湿霜无限期使用。 日本Corectim说明书规定，0.5%制剂治疗4周没有改善，应停止并重新评估；症状改善后，也要判断是否仍需继续，不能漫无目的地长期涂抹。 美国卢可替尼治疗特应性皮炎的定位是短期及非连续的慢性使用。症状控制后应停止，如果规定周期后没有改善，也需要重新评估。 白癜风复色往往需要更长时间，FDA资料指出部分患者可能需要超过24周才能获得满意反应，这与治疗特应性皮炎的疗程不能混为一谈。两种药应该如何选择？ 如果患者确诊为特应性皮炎，可以从以下方面判断： 所在国家批准了哪一种药及哪项适应证； 患者年龄是否符合说明书要求； 皮损范围是否超过药物允许面积； 是否合并疱疹、细菌或真菌感染； 以前使用激素、他克莫司或其他药物的效果； 是否正在接受生物制剂或系统性免疫抑制治疗。 如果主要问题是非节段型白癜风，则不能把日本Corectim当成卢可替尼乳膏的廉价替代品。即使同属外用JAK抑制剂，不同适应证所需要的临床证据也不同。总结 Delgocitinib和卢可替尼都是非激素外用JAK抑制剂，但核心差异十分明确： Delgocitinib是抑制JAK1、JAK2、JAK3和TYK2的广谱JAK抑制剂，日本Corectim主要用于特应性皮炎；卢可替尼主要抑制JAK1/2，美国Opzelura同时拥有特应性皮炎和非节段型白癜风适应证。 两种药的百分比不能直接比较，疗效数据也不能跨试验排名。真正合理的选择，应以确诊疾病、年龄、皮损面积、当地批准状态和医生评估为基础。 本文仅用于医学科普，不构成诊断或处方建议。不同国家和地区的适应证、年龄限制、用量及安全警示可能不同，请以当地最新说明书和医生意见为准。 让全球华人更容易获得日本优质医疗。 新特药/干细胞/在线问诊/专家会诊/海外医疗/BNCT治疗。 中国癌症误诊率高？日本医生这样看 40% vs 68.8%：中日癌症生存率差距从哪来？ 为什么很多癌症家庭，会选择日本二次专家会诊？ 为什么一定要做日本专家二次会诊？这个40多岁患者的亲生经历给出答案 BNCT成功率真相：为什么日本癌症5年生存率全球领先？深度拆解中日诊疗差异 一个13岁脑癌孩子的“生命接力赛”：从国内无路可走，BNCT海外医疗点亮希望之光。